Environmental and Genetic Factors That Influence Cardiovascular Disease in African Americans

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2006 by National Heart, Lung, and Blood Institute (NHLBI).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00005485
First received: May 25, 2000
Last updated: April 27, 2006
Last verified: April 2006
  Purpose

This is a prospective study of the environmental and genetic factors that influence the development of cardiovascular disease (CVD) in African American men and women. The cohort is an expansion of the Jackson, Mississippi site of the Atherosclerosis Risk in Communities (ARIC) study and is a partnership among two minority institutions (Jackson State University and Tougaloo College), one majority institution in Jackson, Mississippi (the University of Mississippi Medical Center), the National Institutes of Health (NIH) National Center on Minority Health and Health Disparities (NCMHD), and the National Heart, Lung, and Blood Institute (NHLBI).


Condition
Cardiovascular Diseases
Heart Diseases
Atherosclerosis
Coronary Disease
Hypertension
Cerebrovascular Disorders

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Jackson Heart Study (JHS)

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Estimated Enrollment: 5307
Study Start Date: October 1996
Detailed Description:

BACKGROUND:

Heart disease and stroke remain the first and third leading killers of all Americans, with a disproportionate share of the burden borne by African Americans. Cardiovascular and total mortality are known to be higher among African Americans than among white Americans, but reasons for these differences remain unknown. In addition, well-documented declines in CVD and coronary disease mortality in the past three decades have not been shared equally between blacks and whites. Age-adjusted death rates were identical in both groups in 1980, but by 1994 the rate among African Americans was 14% higher than in whites. The race difference in magnitude of coronary heart disease (CHD) mortality is greater in women than men and higher in middle age, such that CHD deaths tend to occur in blacks about 5 years earlier than in whites. Excess cerebrovascular disease incidence and mortality in blacks are even greater than the differences noted in CHD.

Cardiovascular mortality rates in Mississippi, which are approximately 25% higher than the United States average, are the highest in the United States for all race-sex groups. Age-adjusted CVD mortality for African American women in Mississippi was 75% higher than in white women in 1994. The mortality for African American men was 47% higher than in white men.

Prevalence of hypertension is nearly 40% greater in African Americans than in whites and its sequelae are more frequent and severe. Evidence of target organ damage such as renal failure and left ventricular hypertrophy is more common in black than white hypertensives at comparable levels of blood pressure. Many risk factors are also more common in blacks, including diabetes, high serum lipoprotein levels [Lp(a)], and obesity (in women). Other risk factors, such as elevated total cholesterol, reduced high-density lipoprotein (HDL)-cholesterol, and heavy cigarette smoking, are more common in whites.

DESIGN NARRATIVE:

The Jackson Heart Study (JHS) initial examination, which began in the fall of 2000, included men and women ages 35 to 84, and took 3 years to complete. The coordinating center, located at Jackson State University, collects and analyzes data. The undergraduate training center at Tougaloo College offers coursework to students in public health and epidemiology, and provides practical experience in health research to prepare them for potential careers in these fields. The exam center at the University of Mississippi is responsible for recruiting participants and conducting examinations. JHS is uniquely positioned to answer key questions regarding the excess burden of CVD among African Americans and to address the critical shortage of minority investigators trained in epidemiology and prevention. These questions will be answered by incorporating state-of-the-art physiologic and epidemiologic methods in a stable population-based minority cohort, providing research experience, and building research capabilities at minority institutions. The Second Exam began in September 2005.

  Eligibility

Ages Eligible for Study:   35 Years to 84 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • African American
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005485

Locations
United States, Mississippi
University of Mississippi Medical Center Recruiting
Jackson, Mississippi, United States, 39213
Contact: Dr. Herman W. Taylor    601-984-5630    htaylor@medicine.umsmed.edu   
Principal Investigator: Dr. Herman W. Taylor         
Sponsors and Collaborators
Investigators
Principal Investigator: Asoka Srinivasan Tougaloo College
Principal Investigator: Herman Taylor University of Mississippi Medical Center
Principal Investigator: Herman Taylor Jackson State University
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00005485     History of Changes
Other Study ID Numbers: 5001, N01 HC95170, N01 HC95171, N01 HC95172
Study First Received: May 25, 2000
Last Updated: April 27, 2006
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Atherosclerosis
Arteriosclerosis
Coronary Artery Disease
Arterial Occlusive Diseases
Hypertension
Cardiovascular Diseases
Heart Diseases
Coronary Disease
Cerebrovascular Disorders
Vascular Diseases
Myocardial Ischemia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on September 30, 2014